Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

Amid reports of rare botulism cases in the UK, the country's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety warning for all botulinum toxin type A products, including Botox and other cosmetic injectables.

The regulator said cases of iatrogenic botulism—botulism caused by medical treatment—have been reported following both therapeutic and cosmetic use of botulinum toxin products when the toxin spreads beyond the intended injection site.

"Patients should seek immediate medical advice if they experience signs and symptoms," the MHRA said.

Why Are Botulinum toxin At Risk?

Botulinum toxin medicines are widely used for cosmetic procedures, such as reducing facial wrinkles, as well as for treating conditions including muscle spasms, excessive sweating (hyperhidrosis), and an overactive bladder.

While these medicines are considered safe when used correctly, the MHRA warned that, in very rare cases, the toxin can spread beyond the injection site and cause botulism—a serious and potentially life-threatening condition.

To improve awareness, the regulator has worked with manufacturers to update product information and patient leaflets to more clearly highlight the risk of iatrogenic botulism.

Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study

Symptoms Can Appear Up to Four Weeks Later

The MHRA warned that symptoms may not appear immediately after treatment. They can develop within days or even up to four weeks after receiving a botulinum toxin injection.

Patients are advised to seek immediate medical attention if they experience:

• Difficulty swallowing
• Slurred speech or difficulty talking
• Difficulty breathing or shortness of breath
• Muscle weakness

Who Is at Higher Risk?

According to the MHRA, the risk of serious side effects may be higher in:

• People with underlying neurological disorders
• Those with a history of difficulty swallowing (dysphagia)
• Those with a history of aspiration (inhaling food or fluids into the lungs)
• Patients receiving high doses of botulinum toxin
• Procedures performed outside licensed indications or at unapproved injection sites
• Use of counterfeit or unlicensed botulinum toxin products

Health officials say early recognition of symptoms is critical, as prompt treatment can help prevent serious complications.

"While botulism is a rare infection, it can be serious. There are effective treatments available, and we recommend seeking immediate medical advice if you have had a recent treatment and are experiencing symptoms such as difficulty swallowing," said Dr. Martin Bewley, Consultant in Health Protection at the UK Health Security Agency (UKHSA).

Dr. Alison Cave, Chief Safety Officer at the MHRA, recommended that healthcare professionals and patients be aware of the symptoms of botulism and act quickly if they arise. Importantly, the expert "strongly urged the public to avoid unlicensed products and seek treatment only from appropriately qualified practitioners."

What Is Botulism?

Botulism is a rare but serious illness caused by a toxin produced by the bacterium Clostridium botulinum. The toxin attacks the nervous system and can lead to paralysis, breathing difficulties, and, in severe cases, death if not treated promptly.

Because it can rapidly affect the muscles involved in breathing, botulism is considered a medical emergency.

The US Food and Drug Administration (FDA) has approved a once-daily pill that can lower low-density lipoprotein (LDL), commonly known as "bad" cholesterol, a major risk factor for heart disease.

Developed by Merck, enlicitide, which will be marketed as Lipfendra, is the first FDA-approved oral PCSK9 inhibitor for reducing LDL cholesterol.

Lipfendra has been approved as an adjunct to diet and exercise to reduce LDL cholesterol in adults with primary hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).

The approval is based on two Phase 3 clinical trials showing that Lipfendra can reduce LDL cholesterol to 50–60 mg/dL or even lower in many patients.

"Results from these Phase 3 trials showed treatment with Lipfendra resulted in reductions across other atherogenic lipoproteins associated with atherosclerotic cardiovascular disease (ASCVD) risk, including non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (ApoB)," Merck said.

High LDL cholesterol is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of death globally.

"In two Phase 3 trials, LIPFENDRA led to impressive reductions in LDL-C. Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering," said Dr. Ann Marie Navar, lead author of the clinical trial and associate professor at the University of Texas Southwestern Medical Center.

Also read: Spinal Muscular Atrophy: England to Roll Out Nationwide Newborn Screening From 2027

How Does Lipfendra Work?

Lipfendra is a 20 mg once-daily tablet that works by blocking PCSK9, a protein that regulates LDL receptors in the liver.

Normally, PCSK9 reduces the number of LDL receptors available to remove cholesterol from the bloodstream. By inhibiting this protein, Lipfendra allows more LDL receptors to remain active, enabling the liver to clear more LDL cholesterol from the blood.

Unlike statins, which lower cholesterol by blocking an enzyme the liver uses to produce cholesterol, Lipfendra targets the PCSK9 pathway. It is also the first oral medicine in this class, whereas existing PCSK9 inhibitors are administered as injections.

What Did the Clinical Trials Show?

The FDA approval was supported by two Phase 3 studies, including a 24-week trial involving 2,912 participants, which demonstrated significant reductions in LDL cholesterol.

The studies found that:

• Lipfendra lowered LDL cholesterol by up to 60%.
• Many participants achieved LDL levels of 50–60 mg/dL or lower.
• The drug also reduced non-HDL cholesterol and ApoB, two additional markers associated with cardiovascular risk.
• Side effects were similar to those seen with placebo.

The cholesterol-lowering effect was comparable to that seen with injectable PCSK9 inhibitors.

Merck is now conducting a cardiovascular outcomes trial to determine whether Lipfendra also lowers the risk of heart attacks, strokes and cardiovascular death, as injectable PCSK9 inhibitors have previously been shown to do.

Lipfendra: How Much Does It Cost?

Merck said Lipfendra will be available in the United States within the next few weeks. The company has set a list price of $315 for a 30-day supply, according to Merck spokeswoman Julie Cunningham.

Who Could Benefit From Lipfendra?

Lipfendra is intended for adults with hypercholesterolemia, a condition characterized by elevated LDL cholesterol that can lead to plaque buildup in the arteries.

The drug may particularly benefit:

• Adults with primary hypercholesterolemia.
• People with heterozygous familial hypercholesterolemia (HeFH).
• Patients who need additional LDL lowering despite diet, exercise or statin therapy.
• Individuals looking for an oral alternative to injectable PCSK9 inhibitors.

Breast cancer diagnosed shortly after pregnancy may be more aggressive. According to new research, some young mothers may face poorer outcomes despite having similar types of breast cancer tumors as other women.

A UCLA-led study, published in npj Breast Cancer, found that women diagnosed with hormone receptor-positive (HR+), HER2-negative breast cancer within the first three years after childbirth, especially during the first year, were more likely to have tumors with a higher risk of recurrence.

It therefore indicates that postpartum breast cancer is not simply breast cancer diagnosed after pregnancy but may be a biologically distinct disease.

Breast Cancer In New Mothers

Also read: Could Chemotherapy Soon Be Optional? AstraZeneca and Gilead Drugs Show Promise for Breast Cancer Patients

Researchers analyzed young women with HR-positive, HER2-negative breast cancer using the widely used 21-gene Oncotype DX Recurrence Score, a genomic test that helps predict the likelihood of cancer recurrence and whether chemotherapy may be beneficial.

They discovered that tumors diagnosed during the first three years after childbirth had significantly higher recurrence rates than tumors in women who had never given birth.

The highest scores were observed among women diagnosed within the first year after delivery.

"Our findings suggest that the first three years after childbirth represent a distinct biological window during which hormone receptor-positive breast cancers may behave more aggressively," the researchers observed.

The study also provides one of the first genomic definitions of this high-risk postpartum period rather than relying solely on clinical observations.

Can Childbirth Change Breast Cancer Outcome?

Also read: You Know What? Wearing Black Underwears Do Not Cause Breast Cancer - Myths Busted By Expert

Researchers believe that the answer to that question lies in what happens to the breast after breastfeeding comes to an end.

After pregnancy and lactation, the breast undergoes a natural process called mammary gland involution, during which the milk-producing tissue shrinks, and the breast returns to its pre-pregnancy state.

While this change is normal, it creates a temporary environment that features inflammation, weakened immune system, and extensive tissue restructuring.

According to a recent review published in Breast Cancer Research, these biological changes may unintentionally create conditions that help dormant cancer cells survive, grow, and spread. Researchers describe this postpartum remodeling as a "tumor-promoting microenvironment."

These processes may partly explain why postpartum breast cancers are often diagnosed at more advanced stages and have poorer outcomes than breast cancers in women of similar age who have not recently given birth.

Effect Of Delay In Childbirth

The findings hold importance as breast cancer rates among younger women continue to increase worldwide just when women are getting pregnant later in their lives. Previous studies have indicated that breast cancer detected after pregnancy behaves differently.

"The medical community has long recognized that breast cancers diagnosed after pregnancy can behave differently," UCLA researchers said. "With breast cancer rates among younger women increasing, scientists have been studying whether delayed timing of first pregnancy may help explain some of that trend."

Because pregnancy and breastfeeding naturally change breast tissue, warning signs like lumps or breast firmness can sometimes be mistaken for normal postpartum changes. This may delay diagnosis and allow cancers to progress before they are detected.